Form 4: Regeneron CFO Fenimore Reports Equity Awards & Sales

Christopher R. Fenimore, EVP Finance CFO of Regeneron Pharmaceuticals, Inc., reported the acquisition of restricted stock and stock options, alongside a disposition of shares for tax purposes.

Summary

• Christopher R. Fenimore, EVP Finance CFO, reported transactions involving Regeneron Pharmaceuticals, Inc. common stock and derivative securities.
• On December 5, 2025, Fenimore acquired 3,027 shares of common stock as a Restricted Stock award under the Second Amended and Restated 2014 Long-Term Incentive Plan. These shares vest 50% on December 5, 2027, and 50% on December 5, 2029.
• Also on December 5, 2025, Fenimore was granted 14,924 Non-Qualified Stock Options with an exercise price of $726.71. These options vest in four equal annual installments, commencing one year after the grant date, and expire on December 5, 2035.
• On December 8, 2025, Fenimore disposed of 992 shares of common stock at a price of $712.94 per share, likely for tax withholding purposes related to the equity awards.
• Following these transactions, Fenimore directly beneficially owns 18,300 shares of common stock.
• Indirect beneficial ownership includes 1,548 shares in a 401(k) Plan, 1,897 shares in a trust for the spouse, 25 shares in a trust for a daughter, and 25 shares in a trust for a son.
• Fenimore also directly beneficially owns 14,924 Non-Qualified Stock Options.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as it reflects ongoing executive incentive alignment through equity awards, a standard practice. The disposition of shares is for tax purposes, which is neutral.

Positives

• Christopher R. Fenimore, EVP Finance CFO, received an award of 3,027 shares of restricted common stock, aligning his interests with long-term shareholder value.
• Fenimore was granted 14,924 Non-Qualified Stock Options, providing further incentive for future company performance.

Negatives

• Fenimore disposed of 992 shares of common stock at $712.94 per share, reducing his direct beneficial ownership, likely to cover tax obligations associated with the equity awards.

Risks

• The value of the restricted stock and stock options is subject to the future market performance of Regeneron Pharmaceuticals, Inc. common stock.
• Equity compensation plans can lead to dilution for existing shareholders over time as new shares are issued upon vesting or exercise.

Future Outlook

The restricted stock award vests 50% on December 5, 2027, and 50% on December 5, 2029. The non-qualified stock options vest in four equal annual installments, commencing one year after the grant date of December 5, 2025, and expire on December 5, 2035.

Management Comments

• Christopher R. Fenimore, EVP Finance CFO, reported these transactions as part of his compensation and beneficial ownership changes.

Industry Context

This Form 4 filing details individual executive compensation and beneficial ownership changes, which are routine disclosures and do not inherently reflect broader industry trends or competitive positioning.

Comparison to Industry Standards

• The structure of equity awards, including restricted stock and stock options with multi-year vesting schedules, is a common practice in executive compensation across the pharmaceutical and biotechnology industries, aiming to incentivize long-term performance and retention.
• The disposition of shares for tax withholding (transaction code 'F') is a standard procedure for executives receiving equity compensation, consistent with practices at comparable companies.

Corporate Governance

Stakeholder Impact

• Shareholders: Experience minor dilution from the issuance of new equity awards, but the awards aim to align executive incentives with long-term shareholder value.
• Employees (specifically the CFO): Christopher R. Fenimore's compensation package is enhanced through these equity awards, providing a significant incentive tied to company performance.

Next Steps

• Vesting of 50% of the restricted stock award on December 5, 2027.
• Vesting of 50% of the restricted stock award on December 5, 2029.
• Annual vesting installments for the non-qualified stock options, commencing one year after December 5, 2025.

Key Dates

Keywords

Regeneron Pharmaceuticals, REGN, Christopher R. Fenimore, Form 4, SEC filing, executive compensation, restricted stock units, stock options, insider transactions, equity awards, CFO